St. Vincent's Institute of Medical Research

Howard Florey Institute

Beijing University of Technology

Medvet Science Pty Ltd

Central Adelaide Local Health Network Inc.

Howard Florey Institute of Experimental Physiology and Medicine

Michael William Parker

Siew Yeen Chai

Keith G Watson

Angel Francisco Lopez

Frederick A O Mendelsohn

William John McKinstry

Anthony Lloyd Albiston

Philip E Thompson

Joanna Woodcock

Christopher James Bagley

Jamie Rossjohn

Simon John Mountford

Timothy Robert Hercus

Guido Hansen

Tracy Leah Nero

Luke Anthony Miles

Siying Ye

Craig J Morton

Hooi Ling Ng

The present disclosure relates generally, but not exclusively, to compounds and their use in therapy, to compositions and agents comprising said compounds, to methods of treatment using said compounds, and their use in the manufacture of medicaments. The disclosure further relates to inhibitors of IRAP and their use in the treatment or prevention of Alzheimer's disease and the treatment and prevention of memory and cognitive disorders.

4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors

The present disclosure relates generally to a protocol to treat or prevent diseases or conditions associated with pathological forms of amyloid beta (A&#x3b2;), including Alzheimer's disease. Enabled herein is a reagent for use in the treatment and prophylaxis of A&#x3b2;-associated pathological conditions.

Antibody therapy for amyloid beta disease

The present invention relates generally to the field of crystallography. More particularly, the present invention provides crystalline forms of a complex between granulocyte macrophage-colony stimulating factor (GM-CSF) and its receptor (GM-CSFR). The present invention further provides methods for the design and selection of modulators of GM-CSF/GM-CSFR interaction and signaling as well as signaling of other cytokines.

Crystalline composition of GM-CSF/GM-CSFR

The present invention relates to inhibitors of insulin-regulated aminopeptidase (IRAP) and methods for inhibiting same, as well as compositions comprising said inhibitors. In particular, the inhibitors of the present invention may be useful in therapeutic applications including enhancing memory and learning functions.

Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof

The present invention provides a cytokine-binding domain or portion thereof which binds to at least one cytokine and is capable of transducing a cytokine signal through a single cytokine receptor, said domain comprising a portion of the B'-C&#x2032; loop of domain 4 of a &#x3b2;chain or analogous structure of a cytokine receptor. In another aspect of the invention there is provided a method of identifying a compound having cytokine agonist or antagonist activity, said method including subjecting a potential cytokine agonist and/or cytokine antagonist compound to a cytokine binding domain or portion thereof wherein said domain binds to at least one cytokine and is capable of transducing a cytokine signal through a single cytokine receptor, said domain comprising a portion of the B&#x2032;-C&#x2032; loop of domain 4 of a &#x3b2;chain or analogous structure of the cytokine receptor; and determining the presence of an agonist or antagonist response of the compound on the activity of a cytokine. In a preferred aspect there is provided a method fo identifying a GM-CSF, IL-3 and IL-5 agonist or antagonist, said method including: subjecting a potential agonist or antagonist to a GM-CSF, IL-3 and IL-5 binding domain or portion thereof wherein said domain binds to at least one of the cytokines and is capable of transducing a cytokine signal through a single cytokine receptor, said domain comprising a portion of the B&#x2032;-C&#x2032; loop of domain 4 of a &#x3b2;chain or analogous structure of the cytokine receptor; and determining the presence of a agonist or antagonist response from the compound on the activity of GM-CSF, IL-3 and IL-5.

Cytokine binding domain of cytokine receptors

Growing community of inventors

Newport, Australia

Michael William Parker